# GLP-1 and Metabolic Research Digest: Efficacy and Safety of CagriSema for Metaboli&#8230;

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/glp-1-and-metabolic-research-digest-efficacy-and-safety-of-cagrisema-fo-sep-2026/
> **Published:** 2026-09-20T09:20:07-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:20-04:00
> **Clinical Summary:** cannabis science digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan.

---

CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments.

Clinical Insight | CED Clinic
This curated glp-1 and metabolic research digest delivers practical physician analysis of 3 timely investigations. By reviewing primary study cohorts, including Efficacy and Safety of CagriSema for Metabolic Outcomes: Sys, healthcare providers and patients can observe reproducible trends in therapeutic use, adverse exposure patterns, and pharmacological mechanisms. Grounding clinical recommendations in primary data ensures that patient counseling remains calibrated, safe, and medically sound across all treatment pathways. Evaluating emerging cohort data with clinical discipline ensures that therapeutic decisions remain anchored in verified primary outcomes rather than unmonitored commercial trends.

DigestCannabis ScienceRegulationPublic HealthClinical Practice

AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers.
Primary TopicCurated updates on Efficacy and Safety of CagriSema for Metabolic Out.
Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42763732/)

A structured CED Clinic overview of 3 key developments in cannabis regulation, market milestones, and scientific research.

What This Study Teaches Us
Across these 3 publications, primary findings reveal that CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD -6.60%; 95%CI: -8.51 to -4.68; P

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).